Despite a recent dip, Haemonetics' robust financials hint at potential long-term stock value growth. High ROE and profit reinvestment suggest promising earnings growth, with analysts predicting continued expansion.
Despite the falling share price, the consistent growth in revenue and EPS could present an investment opportunity if the stock has fallen unfairly. Market expectations may have been unreasonable in the past.
Shareholders appear to hang onto Haemonetics, expecting it to keep beating market trends, due to its projected solid growth. Despite a high P/E, the predicted limited risk of an earnings drop keeps the share price stable.
RDK79 :
Netflix should sue the crap out of Bloomberg! These unsubstantiated postings by financial ‘experts’ without any accountability is amazing. Wall-street is bulletproof